The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

被引:51
|
作者
Conti, Rena M. [1 ,2 ]
Bach, Peter B. [3 ]
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, New York, NY 10021 USA
关键词
PHYSICIAN RELATIONS; COST; INTEGRATION;
D O I
10.1377/hlthaff.2014.0540
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The federal 340B program gives participating hospitals and other medical providers deep discounts on outpatient drugs. Named for a section of the Veterans Health Care Act of 1992, the program's original intent was to help low-income and uninsured patients. But the program has come under scrutiny by critics who contend that some hospitals exploit the drug discounts to generate profits instead of either investing in programs for the poor or passing the discounts along to patients and insurers. We examined whether the program is expanding in ways that could maximize hospitals' ability to generate profits from the 340B drug discounts. We matched data for 960 hospitals and 3,964 affiliated clinics registered with the 340B program in 2012 with the socioeconomic characteristics of their communities from the US Census Bureau's American Community Survey. We found that hospital-affiliated clinics that registered for the 340B program in 2004 or later served communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and clinics that registered for the program before 2004. Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.
引用
收藏
页码:1786 / 1792
页数:7
相关论文
共 50 条
  • [31] Availability of pharmacies participating in the 340B Drug Pricing Program, 2016
    Guadamuz, Jenny S.
    Qato, Dima M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 429 - 430
  • [32] AVAILABILITY OF PHARMACIES PARTICIPATING IN THE 340B DRUG PRICING PROGRAM, 2016
    Guadamuz, J.
    Qato, D.
    VALUE IN HEALTH, 2018, 21 : S97 - S97
  • [33] Perverse Incentives - HIV Prevention and the 340B Drug Pricing Program
    Marcus, Julia L.
    Killelea, Amy
    Krakower, Douglas S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (22): : 2064 - 2066
  • [34] Community social vulnerability and the 340B Drug Pricing Program: Evaluating predictors of 340B participation among critical access hospital
    Owsley, Kelsey M.
    Karim, Saleema A.
    JOURNAL OF RURAL HEALTH, 2024,
  • [35] Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability
    Knox, Ryan P.
    Kesselheim, Aaron S.
    Sarpatwari, Ameet
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (17): : 1647 - 1648
  • [36] Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study
    Jianhui Hu
    David R. Nerenz
    BMC Health Services Research, 25 (1)
  • [37] Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Karen Mulligan
    John A. Romley
    Rebecca Myerson
    BMC Research Notes, 14
  • [38] Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan, Karen
    Romley, John A.
    Myerson, Rebecca
    BMC RESEARCH NOTES, 2021, 14 (01)
  • [39] 340B Drug Pricing Program The expansion and its effect on cancer care
    Fauer, Alex
    Friese, Christopher R.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2019, 23 (02) : 217 - 219
  • [40] Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program
    Karralli, Rusol
    Tipton, Joyce
    Dumitru, Doina
    Scholz, Lisa
    Masilamani, Santhi
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (17) : 1489 - 1495